Literature DB >> 11523053

Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression.

A Barghorn1, P Komminoth, D Bachmann, K Rütimann, P Saremaslani, S Muletta-Feurer, A Perren, J Roth, P U Heitz, E J Speel.   

Abstract

For several reasons, chromosome 3p is thought to be involved in the pathogenesis of sporadic endocrine pancreatic tumours (EPTs): von Hippel-Lindau's disease (VHL gene at 3p25.5) is associated with EPTs; 3p is frequently involved in solid human tumours; and comparative genomic hybridization has identified frequent losses at 3p in EPTs. This study investigated 99 benign and malignant tumours, including 20 metastases, from 82 patients, by microsatellite loss of heterozygosity (LOH) analysis and fluorescence in situ hybridization (FISH) in order to evaluate the importance of chromosome 3p deletions in the molecular pathogenesis and biological behaviour of EPTs, to elaborate a common region of deletion, and to narrow down putative tumour suppressor gene loci. Allelic losses of 3p were found in 58/99 (58.6%) of tumours in 45/82 (54.9%) patients; analysis of seven microsatellite markers (3p26-p21) revealed a common region of LOH at 3p25.3-p23. The LOH frequency was significantly higher in malignant than in benign neoplasms (70.2% versus 28.0%; p=0.001). In addition, a strong correlation was found between the loss of alleles on chromosome 3p and clinically metastatic disease (LOH of 73.7% in metastasizing versus 41.5% in non-metastasizing tumours; p=0.008). EPTs from these patients showed a tendency towards losing large parts or the entire short arm of chromosome 3 with tumour progression. Furthermore, FISH analysis revealed complete loss of chromosome 3 in ten out of 37 EPTs (27%). These results indicate that a putative tumour suppressor gene at 3p25.3-p23 may play a role in the oncogenesis of sporadic EPTs and that losses of larger centromeric regions are associated with metastatic progression. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2001        PMID: 11523053     DOI: 10.1002/path.886

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  17 in total

1.  Insulin secretion and insulin-producing tumors.

Authors:  Jean-Marc Guettier; Phillip Gorden
Journal:  Expert Rev Endocrinol Metab       Date:  2010-03-01

2.  Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology.

Authors:  Lester J Layfield; Hormoz Ehya; Armando C Filie; Ralph H Hruban; Nirag Jhala; Loren Joseph; Philippe Vielh; Martha B Pitman
Journal:  Diagn Cytopathol       Date:  2014-04       Impact factor: 1.582

3.  Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors.

Authors:  A Barghorn; E J Speel; B Farspour; P Saremaslani; S Schmid; A Perren; J Roth; P U Heitz; P Komminoth
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

4.  Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases.

Authors:  Nicole Posorski; Daniel Kaemmerer; Guenther Ernst; Patricia Grabowski; Dieter Hoersch; Merten Hommann; Ferdinand von Eggeling
Journal:  Clin Exp Metastasis       Date:  2011-06-17       Impact factor: 5.150

5.  Xq25 and Xq26 identify the common minimal deletion region in malignant gastroenteropancreatic endocrine carcinomas.

Authors:  Cinzia Azzoni; Lorena Bottarelli; Silvia Pizzi; Tiziana D'Adda; Guido Rindi; Cesare Bordi
Journal:  Virchows Arch       Date:  2005-10-22       Impact factor: 4.064

Review 6.  Criteria for malignancy in gastrointestinal endocrine tumors.

Authors:  Cesare Bordi; Tiziana D'Adda; Cinzia Azzoni; Silvia Pizzi; Lorena Bottarelli; Francesca Mormandi; Tommaso Antonetti; Tu Vinh Luong; Guido Rindi
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

Review 7.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

Authors:  Thorvardur R Halfdanarson; Joseph Rubin; Michael B Farnell; Clive S Grant; Gloria M Petersen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

Review 8.  Molecular profiles of gastroenteropancreatic endocrine tumors.

Authors:  Aurel Perren; Martin Anlauf; Paul Komminoth
Journal:  Virchows Arch       Date:  2007-08-08       Impact factor: 4.064

9.  Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas.

Authors:  Ibrahim Alkatout; Juliane Friemel; Barbara Sitek; Martin Anlauf; Patricia A Eisenach; Kai Stühler; Aldo Scarpa; Aurel Perren; Helmut E Meyer; Wolfram T Knoefel; Günter Klöppel; Bence Sipos
Journal:  Mod Pathol       Date:  2014-06-20       Impact factor: 7.842

10.  Analysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer's disease, cancer risk, and cholesterol.

Authors:  Yang Chen; Chun Xu; Sam Harirforoosh; Xingguang Luo; Ke-Sheng Wang
Journal:  J Psychiatr Res       Date:  2017-09-27       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.